The results show the importance of diagnosing lung conditions through spirometry as well the necessity for more effective therapies for patients without COPD.
Dual bronchodilators, often prescribed for individuals with respiratory symptoms and a history of smoking, but do not have chronic obstructive pulmonary disease (COPD), are ineffective, according to a study published earlier this month.
The findings were published in the New England Journal of Medicine and simultaneously presented at the European Respiratory Society International Congress.
The results show the importance of diagnosing lung conditions through spirometry as well the necessity for more effective therapies for patients without COPD.
The researchers said they conducted the study because there is a lack of data in this population of individuals with a smoking history and preserved lung function but have symptoms of respiratory problems and are treated with COPD medications, including inhaled bronchodilators and glucocorticoids.
"Because spirometry is infrequently performed in primary care, it is unclear whether physicians believe they are treating COPD or whether they believe COPD medications are effective for these patients," the authors wrote.
In the 12-week, randomized, double-blinded study, which was part of the Redefining Therapy in Early COPD for the Pulmonary Trials Cooperative (RETHINC), researchers enrolled 535 adults with symptoms of COPD, aged 40-80, at 1 of 20 US medical centers. Twice each day, study participants used an inhaler that contained either medication or a placebo.
By the end of the trial, some adults in intervention group and the control groups saw slight respiratory improvements, defined as coughing less, producing less phlegm, or feeling less winded, as evaluated through the St. George’s Respiratory Questionnaire.
However, there were no statistically significant differences between those receiving medication or placebo; 56% (128 of 227) of participants who received the medication saw respiratory symptom improvements, compared with 59% (144 of 244) in the placebo group.
"Further research is urgently needed to better understand and treat the respiratory disease in these persons," the authors concluded.
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Higher Dietary Magnesium Intake Linked to Reduced Frailty Risk in Patients With COPD
December 9th 2024Higher dietary magnesium intake is associated with a reduced risk of frailty in patients with chronic obstructive pulmonary disease (COPD), emphasizing its potential role in improving clinical outcomes.
Read More